
Phenotypic drug discovery at


ESTEVE


Focus on PAIN



• Target-based screening








Ion Channels & Transporters

Cell-based screening




• In Vivo screening





Strategies

Cell-based – Cell line characterization



In the pain pathway there are different locations where to act...

© ESTEVE, 2015

F11 cell line


F11 cell line is derived from the fusion of a mouse embryonic neuroblastoma (N18TG-2) and rat dorsal root ganglion (DRG) neurons. When differentiated in the presence of cAMP, this cell line exhibit many properties of neuronal cells, including action potentials, extensive neurite outgrowth, synthesis of neurotransmitters, expression of neuropeptide receptors and voltage-gated ion channels (Jow et al 2006).

ND7/23 cell line

ND7/23 is a neuroblastoma x DRG neuron hybrid cell line that when differentiated shows neuronal-like properties as neurite outgrowth and action potentials (Dunn et al 1991).


DRG primary cultures

Cells from different providers are being studied




When neurons transmit pain, they become excited by different stimuli, noxius painful stimuli in normal conditions, but also innocuous sensory stimuli can be perceived as painful in hypersensitive conditions such in neuropathic pain ...

KCl induced neuronal depolarization as a general excitatory stimuli...



Will these stimuli and readouts mimic physiological responses?

Electrical depolarization as a more physiological excitatory stimuli...



Excitable cells like neurons or neuronal-like cells are best studied using patch-clamp techniques where a single type or multiple types of ion channels can be studied as well as whole cell action potentials. Immortalized dorsal root ganglion cells have been shown to fire action potentials in response to current injection and they elicit both voltage and ligand-gated currents corresponding to channels present in native cells (Raymon et al 1999).

In Vivo-based – Compound selection

A critical issue due to assay low throughput

>=5mg unique structures and Soluble in DMSO

No mixtures

17,825

OK or Not Tested

- Chem. Stab. (17,794)
- Citotox (14,616)
- •hERG (14,418)
- AMES (14,417)

Reference
Compounds/
Named Cpds
13,115

"Orphan target": do not hit any target at the tested concentrations

7,785

14,417


CYPs determined (and OK at $1\mu M$ or $10 \mu M$)

- Reviewed one by one, excluding non interesting cpds (reactive groups,...)
- Diversity
- Less probability of hERG
- Higher number of targets tested





Formalin test (Phase II) in mice (40 mg/kg, i.p.; N=5)

The assay should have a reasonable throughput and be able to detect as many type of analgesics as possible → Formalin test in mice









In Vivo-based - Screening

Next steps:

Target deconvolution

Similarity prediction software



Similarity Ensemble Approach

Ligand



Target



Discovering your pharmacology profiles

Pythia predicts both therapeutic targets and off-targets for molecules. Medical indications are also suggested.


3,150 targets and 90 disease areas are considered

Selectivity panels





Phenotypic screening challenges - Summary



Challenge 1: Which are the best compounds to be tested focused on the indication? Combination of targets → multimodality.

Challenge 2: Which are the best assays and more translational readouts in complex disease/behaviours like pain?

Challenge 3: Which are the best tools for target deconvolution?

ComputationalExperimental

Thank you very much for your attention!

